Helping donors and funders carry out vaccine development programs
VFI supports the vision of a healthier world with tried and trusted expertise and network.
VFI is striving to open up access to relevant knowledge for the development of affordable and efficient adjuvanted vaccines. VFI’s funding by the Bill & Melinda Gates Foundation and the European Commission underline VFI’s not-for-profit engagement for the benefit of developing countries.
Current funders
Bill & Melinda Gates Foundation (BMGF)
GHDC
GHDC
Reference:
Marcandalli, J. et al. Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus. Cell 176, 1420-1431.e17 (2019).
Coalition for Epidemic Preparedness Innovations (CEPI)
CEPI
CEPI
European Commission (EC) / Swiss State Secretariat for Education, Research and Innovation (SERI)
EHVA
EHVA
ISIDORe
ISIDORe
BAXERNA
BAXERNA
TBVAC-Horizon
TBVAC-Horizon
UltiMalVax
UltiMalVax
OptiViVax
OptiViVax
National Institutes of Health (NIH)
Adjuvants for Group A Streptococcal Vaccines (GAS)
Adjuvants for Group A Streptococcal Vaccines (GAS)
NIH/NIAID Vaccine Adjuvant Development Program
NIH/NIAID Vaccine Adjuvant Development Program
Bill & Melinda Gates Foundation (BMGF)
VAGH
VAGH
Visit websiteEuropean Commission (EC)
TRANSVAC
TRANSVAC
Reference:
Geels, M. J. et al. TRANSVAC research infrastructure – Results and lessons learned from the European network of vaccine research and development. Vaccine 33, 5481–5487 (2015)
ENOVA
ENOVA
Reference:
Schijns, V. et al. Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunol Rev 296, 169–190 (2020) and Lemoine, C. et al. Technological Approaches for Improving Vaccination Compliance and Coverage. Vaccines 8, 304 (2020)